|
1
|
Allais C, Bernhardson D, Brown AR, Chinigo GM, Desrosiers JN, DiRico KJ, Hotham I, Jones BP, Kulkarni SA, Lewis CA, Lira R, Loach RP, Morse PD, Mousseau JJ, Perry MA, Peng Z, Place DW, Rane AM, Samp L, Singer RA, Wang Z, Weisenburger GA, Yayla HG, Zanghi JM. Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19. Org Process Res Dev 2023:acs.oprd.2c00375. [PMID: 37552749 PMCID: PMC9924092 DOI: 10.1021/acs.oprd.2c00375] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Indexed: 02/05/2023]
Abstract
Lufotrelvir was designed as a first in class 3CL protease inhibitor to treat COVID-19. Development of lufotrelvir was challenged by its relatively poor stability due to its propensity to epimerize and degrade. Key elements of process development included improvement of the supply routes to the indole and lactam fragments, a Claisen addition to homologate the lactam, and a subsequent phosphorylation reaction to prepare the prodrug as well as identification of a DMSO solvated form of lufotrelvir to enable long-term storage. As a new approach to preparing the indole fragment, a Cu-catalyzed C-O coupling using oxalamide ligands was demonstrated. The control of process-related impurities was essential to accommodate the parenteral formulation. Isolation of an MEK solvate followed by the DMSO solvate ensured that all impurities were controlled appropriately.
Collapse
Affiliation(s)
- Christophe Allais
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - David Bernhardson
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Adam R. Brown
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Gary M. Chinigo
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | | | - Kenneth J. DiRico
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Ian Hotham
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Brian P. Jones
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Samir A. Kulkarni
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Chad A. Lewis
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Ricardo Lira
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Richard P. Loach
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Peter D. Morse
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - James J. Mousseau
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Matthew A. Perry
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Zhihui Peng
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - David W. Place
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Anil M. Rane
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Lacey Samp
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Robert A. Singer
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Zheng Wang
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| | | | - Hatice G. Yayla
- Medicine Design, Pfizer
Inc., Groton, Connecticut06340, United States
| | - Joseph M. Zanghi
- Chemical Research and Development, Pfizer
Inc., Groton, Connecticut06340, United States
| |
Collapse
|
|
2
|
Singer RA, Monfette S, Bernhardson D, Tcyrulnikov S, Hubbell AK, Hansen EC. Recent Advances in Nonprecious Metal Catalysis. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Robert A. Singer
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - David Bernhardson
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Sergei Tcyrulnikov
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Aran K. Hubbell
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Eric C. Hansen
- Pfizer Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
|
3
|
Affiliation(s)
- Robert A. Singer
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - David Bernhardson
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Sergei Tcyrulnikov
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Aran K. Hubbell
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Eric C. Hansen
- Pfizer Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
|
4
|
Bernhardson D, Brandt TA, Hulford CA, Lehner RS, Preston BR, Price K, Sagal JF, St. Pierre MJ, Thompson PH, Thuma B. Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin. Org Process Res Dev 2014. [DOI: 10.1021/op400289z] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- David Bernhardson
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Thomas A. Brandt
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Catherine A. Hulford
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Richard S. Lehner
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Brian R. Preston
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Kristin Price
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - John F. Sagal
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Michael J. St. Pierre
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Peter H. Thompson
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| | - Benjamin Thuma
- Chemical Research and Development, ‡Medicinal Chemistry, §Research Analytical, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340 United States
| |
Collapse
|
|
5
|
Bahnck K, Tao Y, Shavnya A, Lilley S, Andrews M, Aspnes G, Bernhardson D, Bill D, Bundesmann M, Dow R, Karki K, Le T, Li Q, Munchhof M, Nematalla A, Nihlawi M, Patel L, Perreault C, Waldo M. Efficient Synthesis of 4-Amino-2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidin-5-ones: Practical Access to a Novel Chemotype in the Development of DGAT-1 Inhibitors. SYNTHESIS-STUTTGART 2012. [DOI: 10.1055/s-0032-1316756] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|